NCT06033170View on ClinicalTrials.gov

Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage

NANot yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2025

Conditions
Postpartum Hemorrhage
Interventions
DEVICE

CELOX™ PPH

Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.

Sponsors

Lead Sponsor

Medtrade
All Listed Sponsors
collaborator

Charite University, Berlin, Germany

OTHER

lead

Medtrade

INDUSTRY

NCT06033170 - Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage | Biotech Hunter | Biotech Hunter